A real-world study of pegcetacoplan for treatment of geographic atrophy showed significantly better outcomes than the pivotal clinical trials in patients who had symptomatic vision loss.
Researchers hypothesized that a composite scoring system for sleep apnea would be a more effective predictor of cardiovascular risk than the standard apnea-hypopnea index.